SANDRA FERRAZ: Open Payments
NPI 1265026272 · PROVIDENCE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,628 in 101 payments from 16 companies in 2025. Trend: 2023 $3,205 · 2024 $2,064 · 2025 $2,628
Food & beverage: $2,529Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $510 |
| Gilead Sciences, Inc. | 13 | $416 |
| Ardelyx, Inc. | 11 | $321 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $271 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $267 |
| Janssen Biotech, Inc. | 5 | $222 |
| Aimmune Therapeutics, Inc. | 4 | $97 |
| Madrigal Pharmaceuticals | 3 | $90 |
| PFIZER INC. | 5 | $83 |
| QOL Medical, LLC | 2 | $80 |
Products named: IBSRELA, XIFAXAN, TREMFYA, ENTYVIO, CREON, SKYRIZI, Livdelzi, LINZESS.
Industry payments across RI — which companies pay providers there.
